| Literature DB >> 35742148 |
Aleksandra Makarewicz1, Małgorzata Jamka1, Jakub Geltz1, Angelika Śmidowicz1, Marta Kokot1, Nina Kaczmarek1, Edyta Mądry2, Jarosław Walkowiak1.
Abstract
The aim of this meta-analysis was to compare the effects of endurance, strength, and combined training on inflammatory markers and adipokine concentrations in overweight and obese adults. We performed a literature search of the Cochrane Library, PubMed, Scopus, and Web of Science databases and identified 24 randomised control trials published prior to June 2021. Our findings indicate that endurance training was significantly more beneficial than strength training in reducing C-reactive protein (CRP) (standard mean difference (SMD): -1.317, 95% confidence intervals (CI): -2.565, -0.070, p = 0.0385), interleukin 6 (IL-6) (SMD: -0.363, 95% CI: -0.648, -0.078, p = 0.0126), and visfatin (SMD: -0.618, 95% CI: -1.015, -0.222, p = 0.0023) concentrations. Moreover, combined training was more beneficial than strength training alone in lowering tumour necrosis factor-alpha (TNF-α) levels (SMD: 0.890, 95% CI: -0.301, 1.478, p = 0.0030). There were no differences between the effects of different types of training programmes on adiponectin and leptin concentrations. In conclusion, compared with strength training, endurance training is more effective in lowering CRP, IL-6, and visfatin concentrations, while combined training is more beneficial in reducing TNF-α levels in overweight and obese adults. Further studies are needed to determine which type of training has a better effect on adiponectin and leptin concentrations in this population.Entities:
Keywords: C-reactive protein; exercises; inflammation; physical activity; pro-inflammatory cytokines
Year: 2022 PMID: 35742148 PMCID: PMC9222976 DOI: 10.3390/healthcare10061098
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Figure 1PRISMA 2020 flow diagram.
Characteristics of included studies.
| Author | Year | Country (Region) | Groups | Studied Population | Obesity/Overweight Definition | Age [Years] | Sex [% of Women] | ||
|---|---|---|---|---|---|---|---|---|---|
| Jamka et al. [ | 2021 | Poland (Europe) | ET | 52 | 44 | Abdominally obese women | BMI ≥ 30 kg/m2 and | 55 ± 7 1 | 100 |
| Kang et al. [ | 2020 | South Korea (Asia) | ET | 21 | 21 | Post-menopausal obese women | %FM > 30% | 56.67 ± 5.43 1 | 100 |
| Mohammad Rahimi et al. [ | 2020 | Iran (Asia) | ET | 10 | 10 | Sedentary obese men with metabolic syndrome | BMI: 30–40 kg/m2 | 44.8 ± 4.8 1 | 0 |
| Banitalebi et al. [ | 2019 | Iran (Asia) | ET | 17 | 14 | Overweight or obese women with T2DM | BMI: 25–48 kg/m2 | 55.36 ± 5.94 1 | 100 |
| Christensen et al. [ | 2019 | Denmark (Europe) | ET | 16 | 14 | Inactive subjects with abdominal obesity | WHR ≥ 0.5 and/or | 39 ± 14 1 | 75 |
| Nunes et al. [ | 2019 | Brazil (South America) | ET | 13 | 13 | Obese postmenopausal women with no history of physical training practice | %FM > 40% | 62.3 (58.2–66.5) 2 | 100 |
| Ratajczak et al. [ | 2019 | Poland (Europe) | ET | 22 | 22 | Women with simple obesity | BMI ≥ 30 kg/m2 and | 51 ± 8 1 | 100 |
| Martins et al. [ | 2018 | Brazil (South America) | ET | 14 | 8 | Overweight women with high risk for TDM2, no exercising for at least 6 months | BMI > 24.9 kg/m2 and | 64.3 ± 6.7 1 | 100 |
| Oh et al. [ | 2017 | Japan (Asia) | ET 3 | 21 | 20 | Obese sedentary men with nonalcoholic fatty liver disease and no exercise habits | %FM > 25% | 48.2 ± 2.3 5 | 0 |
| Soori et al. [ | 2017 | Iran (Asia) | ET | 8 | NI | Postmenopausal sedentary obese women | BMI ≥ 30 kg/m2 | 45–60 6,7 | 100 |
| Shahram et al. [ | 2016 | Iran (Asia) | ET | 30 | NI | Sedentary young study women | BMI ≥ 25 kg/m2 | 22.4 ± 1.64 1 | 100 |
| Tayebi et al. [ | 2016 | Iran (Asia) | ET | 12 | 11 | Non-athlete men with obesity | %FM > 25% | 21.48 ± 1.46 1,8 | 0 |
| Nikseresht et al. [ | 2014 | Iran (Asia) | ET | 12 | NI | Sedentary overweight or obese men with no regular exercise with no history of any medical condition | BMI > 25 kg/m2 | 39.6 ± 3.7 1 | 0 |
| Donges et al. [ | 2013 | Australia (Australia) | ET | 13 | 13 | Sedentary overweight middle-aged men | NI | 45.4 ± 1.7 5
| 0 |
| Ho et al. [ | 2013 | Australia (Australia) | ET | 19 | 15 | Sedentary to lightly active overweight or obese subjects | BMI ≥ 25 and ≤40 kg/m2 | 55 8 (44–62) 6 | 84 |
| Kadoglou et al. [ | 2013 | Greece (Europe) | ET | 25 | 21 | Overweight or obese subjects with T2DM | BMI ≥ 25 kg/m2 | 58.3 ± 5.4 1 | 72 |
| Venojärvi et al. [ | 2013 | Finland (Europe) | ET | 48 | 39 | Overweight and obese middle-aged men with impaired glucose tolerance | BMI: 25.1–34.9 kg/m2 | 55 ± 6.2 1 | 0 |
| Asad et al. [ | 2012 | Iran (Asia) | ET | 12 | 12 | Sedentary healthy male college students | NI | 22 ± 0.89 1 | 0 |
| Stensvold et al. [ | 2012 | Norway (Europe) | ET | 11 | 11 | Inactive subjects with metabolic syndrome | BMI ≥ 30 kg/m2 or | 49.9 ± 10.1 1 | 23 |
| Sukala et al. [ | 2012 | New Zealand (Australia) | ET | 13 | 9 | Subjects with T2DM and visceral obesity | WC ≥ 88 cm for women or | 51 ± 4 1 | 72 |
| Jorge et al. [ | 2011 | Brazil (South America) | ET | 12 | NI 8 | Overweight or obese subjects with T2DM | BMI: 25–40 kg/m2 | 52.09 ± 8.71 1 | 62 |
| Ahmadizad et al. [ | 2007 | Iran (Asia) | ET | 8 | NI | Sedentary obese healthy men | NI | 41.3 ± 5.1 1 | 0 |
| Hara et al. [ | 2005 | Japan (Asia) | ET | 7 | 7 | Young obese men | BMI > 25 kg/m2 | 19.7 ± 1.3 1 | 0 |
BMI—body mass index; CG—control group; CT—combined training; ET—endurance training; NI—no information; ST—strength training; T2DM—type 2 diabetes mellitus; WC—waist circumference; WHR—waist to hip ratio; %FM—percentage of fat mass. 1 Mean ± standard deviation; 2 Mean and 95% confidence interval; 3 High-intensity interval training; 4 Moderate-intensity continuous training; 5 Mean ± standard error; 6 Range; 7 Data for the total population; 8 Mean; a Studies marked with the same letters were conducted in the same population.
Characteristics of training programmes.
| Author | Year | Groups | Characteristic of Groups/Training | Intensity of Training [%] | Duration of Training | Frequency of Training | Time of Intervention | Supervision |
|---|---|---|---|---|---|---|---|---|
| Jamka et al. [ | 2021 | ET | Cycling on ergometer | 50–70% of HR max | 60 | 3 | 12 | Yes |
| CT | ET: Cycling on ergometer | ET: 50–70% of HR max | ||||||
| Kang et al. [ | 2020 | ET | Endurance exercise performed on a treadmill | 50–60% of HR reserve | 50 | 3 | 12 | Yes |
| ST | 3 sets of 7 exercises with a 1 min rest between sets and a 1 min rest between the different exercises: squat and lunge for the lower body, chest press and vertical fly for the chest, lat pull-downs and long pulls for the back, and crunches for the abdomen | 55–65% of 1 RM | 60 | |||||
| Mohammad Rahimi et al. [ | 2020 | ET | 4 × 4 min intervals of walking/running on a treadmill, with 3 min exercise between each interval | 90% of HR peak (intervals) | 43 | 3 | 12 | Yes |
| ST | 2–3 sets of 7 weight machine exercises of 8–20 repetitions: lateral pull-down, chest press, seated row, triceps push-down, knee flexion, knee extension, and leg press | 40–80% of 1 RM 1 | 45 | |||||
| CT | Exercises were similar to the practices of the other two groups | ET: 90% of HR peak (intervals) | ET: 43 | |||||
| CG | The group was advised not to change their physical activity levels throughout the intervention | N/A | N/A | N/A | ||||
| Banitalebi et al. [ | 2019 | ET | Sprint interval training performed on cycle ergometers at a pedaling rate of 20 rpm | 60–70% of HR max 1 | 50 1 | 3 | 10 | Yes |
| CT | ET: Treadmill or cycle ergometer | ET: 60–70% of HR max 1 | ||||||
| CG | Continued their usual medical care and received diabetes recommendations for self-management | N/A | N/A | N/A | ||||
| Christensen et al. [ | 2019 | ET | High intensive interval exercise performed on an ergometer bicycle | NI | 45 | 3 | 12 | Yes |
| ST | 3–5 sets of 10 exercises | 60–80% of 1 RM 1 | ||||||
| CG | No intervention | N/A | N/A | N/A | ||||
| Nunes et al. [ | 2019 | ET | High-intensity interval bodyweight training; 10 sets of vigorous exercises (30 s of stair climbing and 30 s of body weight squats) interspersed by 60 s of a light walk 2 | >85% of HR max + recovery at 60–70% of HR max | 36 | 3 | 12 | Yes |
| CT | ET: Moderate walking | ET: 70% of HR max | 68 | |||||
| Ratajczak et al. [ | 2019 | ET | Training on cycle ergometers | 60–80% of HR max | 60 | 3 | 13 | Yes |
| CT | ET: Similar as described for ET | ET: 60–80% of HR max | 60 | |||||
| Oh et al. [ | 2017 | ET 3 | 3 sets of 3 min cycling with a 2 min active rest between sets, energy expenditure: 180 kcal | 80–85% of VO2 max (rest at 50% of VO2 max) | 13 | 3 | 12 | Yes |
| ET 4 | Cycling, energy expenditure: 360 kcal | 60–65% of VO2 max | 40 | |||||
| ST | Consisted of sit-ups, leg presses, leg extensions, leg curls, chest presses, seated rows, and pull-down, energy expenditure: 180 kcal | To 60% of 1 RM for lower body exercises | NI | |||||
| Soori et al. [ | 2017 | ET | Water-based training: swimming or walking in the water | 40–60% of HR max 1 | 45 | 3 | 10 | Yes |
| ST | 3 sets of 6 dynamic exercises with free weights of 10–12 repetitions: bench press, lateral pull-down, rowing, leg press, and hip flexion and extension | 40–60% of 1 RM 1 | ||||||
| CT | ET: Swimming | ET: 40–60% of HR max | 44 | |||||
| CG | No intervention | N/A | N/A | N/A | ||||
| Shahram et al. [ | 2016 | ET | Continues raining, distance:1600–3200 m | 60–75% of target HR | NI | 3 | 12 | NI |
| ST | Circuit weight training in 11 stations and included 4 sets with 12 RM | 50–60% of 1 RM | ||||||
| CG | No intervention | N/A | ||||||
| Tayebi et al. [ | 2016 | ET | Running program | 65–85% of HR max 1 | 25–40 1 | 3 | 8 | NI |
| ST | 6 sets of 5 exercises of 3–12 repetitions: leg press, knee extension, lat pulldown, biceps curls, and dead lift | 50–80% of 1 RM | NI | |||||
| CT | ET: Similar as described for ET | ET: 65–85% of HR max 1 | ||||||
| Nikseresht et al. [ | 2014 | ET | Running on a treadmill; 4 sets of 4 min with 3 min recovery intervals | 80–90% of HR max (recovery intervals at 55–65% of HR max) | 25 5 | 3 | 12 | Yes |
| ST | 1–4 sets of 12 exercises of 2–20 repetitions with 1–7 min of rest period: knee extension, bench press, incline bench press, seated row, dead lift, pulley crunches, lat pull-downs, calf raise, hamstring curl, press behind neck, upright row, and arm curl | 40–95% of 1 RM | 40–65 | |||||
| CG | Continued their normal sedentary life | N/A | N/A | N/A | ||||
| Donges et al. [ | 2013 | ET | Cycling with elliptical cross training | 75–80% of HR max | 40–60 1 | 3 | 12 | Yes |
| ST | Whole-body training program, including chest and shoulder press, seated rows, lat pulldown, leg press, leg curls, lunges, machine squats, and deadlifts; 3–4 sets × 8–10 of each exercise | 75–80% of 1 RM 1 | NI | |||||
| CT | ET: Similar as described for ET | ET: 75–80% of HR max | ET: 20–30 | |||||
| CG | No intervention | N/A | N/A | N/A | ||||
| Ho et al. [ | 2013 | ET | Treadmill walking | 60% of HR reserve ± 10 beats/min | 30 | 5 | 12 | No |
| ST | 4 sets of 5 exercises of 8–12 repetitions at 10 RM of leg press, leg curl, leg extension, bench press, and rear deltoid row | NI | ||||||
| CT | ET: Similar as described for ET | ET: 60% of HR reserve ± 10 beats/min | 30 | |||||
| CG | No exercise; subjects were requested to continue their normal physical activity and received a placebo dietary supplement only | N/A | N/A | N/A | ||||
| Kadoglou et al. [ | 2013 | ET | Walking or running on a treadmill, cycling or calisthenics | 60–75% of HR max | 60 | 4 | 26 | Yes |
| ST | 2–3 sets of 8 types of exercises of 8–10 repetitions: seated leg press, knee extension, knee flexion, chest press, lat pulldown, overhead press, biceps curl, and triceps extension | 60–80% of 1 RM | 60 1,2 | |||||
| CT | CT: combined training as in endurance training group and strength training group with following pattern weekly: 1 session of ET programme; 1 session of ST; and 2 sessions combining the types of exercise of both ET and ST in the same session | ET: 60–75% of HR max | 55 1,2 | |||||
| CG | Subjects were encouraged to perform self-controlled, leisure-time physical activity (e.g., walking briskly, cycling outdoors) | Low-to-moderate intensity | 150/week | N/A | ||||
| Venojärvi et al. [ | 2013 | ET | Nordic walking consisted of warm-up exercises including walking for 5 min and stretching of main muscle groups in addition to walking with poles; after the pole walking, the main muscle groups were stretched for 5 min for cool-down | 55–75% of HR reserve 1 | 60 | 3 | 12 | Yes |
| ST | Started with warm-up exercises including cycling or rowing with ergometer for 5 min and stretching of main muscle groups. After that the main part of programme was performed by using regular strength equipment, and training focus was on strength and power exercises of the lower extremities and trunk; muscles of the upper extremities were also trained. Muscle contractions were performed with maximal or high velocity, and external loads were 50–85% from exercise-specific maximal strength, which was determined by the 5RM; At the end of every session, subjects cooled down by cycling or rowing with the ergometer for 5 min and by stretching the main muscle groups | 50–85% from exercise-specific maximal strength, which was determined by the 5 RM | ||||||
| CG | No intervention | N/A | N/A | N/A | ||||
| Asad et al. [ | 2012 | ET | Running program | 65–85% of HR max 1 | 25–40 1 | 3 | 8 | NI |
| ST | 3 sets of 10–15 repetitions 1 of weight training exercise with machines and free loads; the training program contained upper body training and lower body training, such as: bench press, sitting and standing up with halter, leg extension, leg flexion, and leg press, and rowing | NI | NI | |||||
| CT | Trained the sum of ET and ST groups | ET: 65–85% of HR max 1 | ET: 25–40 1 + | |||||
| CG | No intervention | N/A | N/A | N/A | ||||
| Stensvold et al. [ | 2012 | ET | Endurance interval training: treadmill walking or running (self-selected); consisted of 4 intervals of 4 min at and 3 min active recovery period | Intervals: 90–95% of HR peak | 43 | 3 | 12 | Yes |
| ST | 3 sets of 8–12 repetitions; consisted of two different programmes including different muscle groups; the following exercises were performed twice weekly (program 1): low row, bench press, and hack lift; the alternative program was performed once each week (program 2): deltoid exercise (lateral raise exercise), triceps pulldown, biceps curl, and low-row and core exercises (plank exercise) | 60–80% of 1 RM 1 | 40–50 6 | |||||
| CT | ET twice a week and ST once a week | ET: 90–95% of HR peak | ET: 43 | |||||
| CG | No intervention | N/A | N/A | N/A | ||||
| Sukala et al. [ | 2012 | ET | Exercises on a cycle ergometer | 65–85% of HR reserve 1 | 40–60 1 | 3 | 16 | Yes |
| ST | 2–3 sets of 8 exercises of 6–8 repetition with 1 min rest between sets and exercises; exercises were performed using machine weights targeting all the major muscle groups of the body and included: seated leg press, knee extension, knee flexion, chest press, lat pulldown, overhead press, biceps curl, and triceps extension | NI | ||||||
| Jorge et al. [ | 2011 | ET | Cycling.programme | HR corresponding to the lactate threshold | 60 | 3 | 12 | Yes |
| ST | Focused on the large muscle groups and consisted of a 7-exercise circuit as follows: leg press, bench press, lat pull down, seated rowing, shoulder press, abdominal curls, and knee curls | NI | ||||||
| CT | Consisted of ST interchanged with ET performed at the same intensity and half the volume of the ET and ST groups | ET: HR corresponding to the lactate threshold | ||||||
| CG | Light stretching exercises | N/A | N/A | |||||
| Ahmadizad et al. [ | 2007 | ET | Continuous running | 75–85% of HR max | 20–30 1 | 3 | 12 | Yes |
| ST | 4 sets of circuit weight training for 11 stations; the maximum numbers of repetitions in each station was 12; exercises involving the upper and lower body | 50–60% of 1 RM | 50–60 | |||||
| CG | No intervention | N/A | N/A | N/A | ||||
| Hara et al. [ | 2005 | ET | Training on treadmills and cycle ergometers | 40.8–54.8% of VO2 max | 30–45 | 3 | 8 | NI |
| CT | ET: Similar as described for ET | ET: 40.8–54.8% of VO2 max | 80–90 | ET: 3 + | 22 | |||
| CG | No intervention | N/A | N/A | N/A | NI |
CG—control group; CT—combined training; ET—endurance training; HR—heart ratio; N/A—not applicable; NI—no information; RM—repetition maximum; ST—strength training; VO2—oxygen uptake. 1 Increasing progressively over time; 2 The goal duration/volume of training; 3 High-intensity interval training; 4 Moderate-intensity continuous training; 5 Four sets of 4 min training with 3 min recovery; 6 Programme 1:40 min, programme 2:50 min; a Studies marked with the same letters were conducted in the same population.
Inflammatory parameters levels in studied populations.
| Author | Year | Group | CRP [mg/L] | IL-6 [pg/mL] | TNF-α [pg/mL] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Changes | Pre | Post | Changes | Pre | Post | Changes | |||
| Jamka et al. [ | 2021 | ET | 3.87 ± 3.76 2 | 4.34 ± 4.63 2 | 0.47 ± 2.86 2 | 2.19 ± 1.54 2 | 2.34 ± 1.60 2 | 0.16 ± 1.79 2 | 40 ± 52 2 | 36 ± 48 2 | −3 ± 12 2 |
| CT | 3.95 ± 3.85 2 | 4.22 ± 4.29 2 | 0.27 ± 2.99 2 | 1.78 ± 0.91 2 | 2.16 ± 1.14 2 | 0.39 ± 1.11 2 | 38 ± 49 2 | 40 ± 51 2 | 2 ± 16 2 | ||
|
| CT: | ET: | |||||||||
| Kang et al. [ | 2020 | ET | NI | NI | 20.11 ± 2.6 2,3 | 22.34 ± 3.2 2,3,4 | NI | NI | NI | NI | |
| ST | 22.15 ± 5.4 2,3 | 24.2 ± 6.9 2,3,4 | |||||||||
|
| ET: | ||||||||||
| Banitalebi et al. [ | 2019 | ET | NI | NI | NI | 1.89 ± 0.95 2 | 1.21 ± 1.11 2 | −0.67 | NI | NI | NI |
| CT | 2.03 ± 1.08 2 | 1.50 ± 1.32 2 | −0.52 | ||||||||
| CG | 2.12 ± 1.24 2 | 1.88 ± 2.01 2 | −0.23 | ||||||||
|
| |||||||||||
| Christensen et al. [ | 2019 | ET | NI | 33.6 (1.05–66.15) 6 | 0.0 (−32.55–32.55) 6 | NI | 0.7 (0.4–1.1) 6 | 0.0 (−0.4–0.3) 6 | NI | 2.4 (2.0–2.8) 6 | 0.1 (−0.3–0.5) 6 |
| ST | 61.95 (28.35–96.6) 6 | 28.35 (−5.25–63) 6 | 1.1 (0.7–1.5) 6 | 0.4 (0.0–0.8) 6 | 2.5 (2.0–2.9) 6 | 0.2 (−0.3–0.6) 6 | |||||
| CG | 32.55 (−4.2–69.3) 6 | −1.05 (−37.8–35.7) 6 | 0.8 (0.4–1.2) 6 | 0.1 (−0.3–0.5) 6 | 2.4 (1.9–2.9) 6 | 0.1 (−0.4–0.6) 6 | |||||
| Nunes et al. [ | 2019 | ET | NI | NI | NI | 1.4 (0.7–2.0) 8 | 2.6 (1.4–3.9) 8 | 1.2 (0.4–2.1) 8 | NI | NI | NI |
| CT | 1.8 (0.6–3.1) 8 | 1.7 (1.0–2.4) 8 | −0.1 (−1.1–0.9) 8 | ||||||||
|
| |||||||||||
| Ratajczak et al. [ | 2019 | ET | 4.18 ± 2.50 2 | 3.45 ± 2.50 2 | NI | NI | NI | NI | NI | NI | NI |
| CT | 3.49 ± 3.20 2 | 2.52 ± 1.90 2 | |||||||||
|
| CT: | ||||||||||
| Martins et al. [ | 2018 | ET | 0.5 ± 0.5 2 | 0.7 ± 0.6 2 | 40.0% 7,9 | 1.4 ± 1.1 2 | 2.6 ± 2.2 2 | 85.7% 7,9 | NI | NI | NI |
| CT | 0.1 ± 0.1 2 | 0.1 ± 0.1 2 | 0% 7,9 | 1.3 ± 1.8 2 | 1.2 ± 1.1 2 | −7.7% 7,9 | |||||
| Oh et al. [ | 2017 | ET 10 | NI | NI | NI | NI | NI | −0.35 | NI | NI | −0.068 12 |
| ET 11 | 1.06 | 0.003 12 | |||||||||
| ST | 0.63 | 0.092 12 | |||||||||
| Shahram et al. [ | 2016 | ET | NI | NI | NI | 7.16 ± 0.15 2 | 2.71 ± 0.14 2 | NI | 12.31 ± 0.23 2 | 9.16 ± 0.19 2 | NI |
| ST | 7.10 ± 0.21 2 | 2.84 ± 0.34 2 | 12.25 ± 0.27 2 | 9.21 ± 0.24 2 | |||||||
| CG | 7.19 ± 0.15 2 | 7.26 ± 0.13 2 | 12.80 ± 0.24 2 | 12.06 ± 0.25 2 | |||||||
|
| |||||||||||
| Nikseresht et al. [ | 2014 | ET | NI | NI | NI | NI | NI | NI | 2.99 ± 0.64 2 | 2.60 ± 0.54 2 | −11.9% 7 |
| ST | 3.00 ± 0.46 2 | 2.66 ± 0.53 2 | −10.7% 7 | ||||||||
| CG | 2.90 ± 0.74 2 | 2.96 ± 0.64 2 | NI | ||||||||
|
| ET: | ||||||||||
| Donges et al. [ | 2013 | ET | 2.25 ± 0.37 13 | 2.33 ± 0.21 13 | 3 ± 13% 7,13 | 1.94 ± 0.31 13 | 1.28 ± 0.26 13 | –34 ± 11% 7,13 | 4.42 ± 0.33 13 | 3.29 ± 0.29 13 | −26 ± 10% 7,13 |
| ST | 2.21 ± 0.30 13 | 2.38 ± 0.31 13 | 8 ± 9% 7,13 | 2.74 ± 0.69 13 | 1.84 ± 0.53 13 | –33 ± 18% 7,13 | 7.14 ± 0.43 13 | 6.23 ± 0.32 13 | −12 ± 5% 7,13 | ||
| CT | 1.88 ± 0.27 13 | 1.91 ± 0.34 13 | 1 ± 14% 7,13 | 2.35 ± 0.31 13 | 1.91 ± 0.26 13 | –19 ± 6% 7,13 | 5.21 ± 0.66 13 | 4.39 ± 0.41 13 | −16 ± 10% 7,13 | ||
| CG | 1.60 ± 0.09 13 | 1.89 ± 0.32 13 | 18 ± 19% 7,13 | 1.93 ± 0.60 13 | 1.88 ± 0.94 13 | –3 ± 19% 7,13 | 6.11 ± 0.25 13 | 6.19 ± 0.33 13 | 1 ± 7% 7,13 | ||
|
| ET, ST, CT: | ET, ST, CT: | |||||||||
| Ho et al. [ | 2013 | ET | NI | NI | NI | 2.5 (0.0–8.5) 14 | NI | NI | 14.6 (8.1–23.3) 14 | NI | −20.8% 7 |
| ST | 2.3 (0.0–7.4) 14 | 12.0 (6.4–20.0) 14 | −26.9% 7 | ||||||||
| CT | 2.3 (0.0–12.4) 14 | 12.6 (4.3–25.8) 14 | −32.6% 7 | ||||||||
| CG | 3.0 (0.0–13.1) 14 | 10.2 (4.9–17.0) 14 | NI | ||||||||
|
| ET: | ||||||||||
| Kadoglou et al. [ | 2013 | ET | 0.15 ± 0.04 2,16 | NI | −0.05 ± 0.01 2,16 | NI | NI | NI | NI | NI | NI |
| ST | 0.15 ± 0.03 2,16 | 0.011 ± 0.003 2,16 | |||||||||
| CT | 0.14 ± 0.05 2,16 | −0.05 ± 0.009 2,16 | |||||||||
| CG | 0.15 ± 0.04 2,16 | 0.01 ± 0.02 2,16 | |||||||||
|
| |||||||||||
| Venojärvi et al. [ | 2013 | ET | 2.2 ± 0.4 13,16 | NI | −0.5 ± 0.4 13,16 | 11.5 ± 3.3 13 | NI | −0.4 ± 0.9 13 | 5.6 ± 0.4 13 | NI | −0.2 ± 0.3 13 |
| ST | 1.6 ± 0.3 13,16 | 0.3 ± 0.4 13,16 | 7.6 ± 2.3 13 | 0.3 ± 0.5 13 | 5.5 ± 0.8 13 | −0.2 ± 0.4 13 | |||||
| CG | 1.4 ± 0.2 13,16 | −0.1 ± 0.3 13,16 | 4.0 ± 1.1 13 | 0.7 ± 0.8 13 | 4.6 ± 0.3 13 | 0.5 ± 0.2 13 | |||||
|
| |||||||||||
| Stensvold et al. [ | 2012 | ET | NI | NI | −0.10 (1.15–−4.71) 3,18 | NI | NI | 0.2 (−3.5–0.8) 3,18 | NI | NI | −0.13 (0.53–(−1.16)) 18 |
| ST | 0.37 (2.38–(−1.72)) 3,18 | 0.3 (−5.4–7.2) 3,18 | 3.9 ± 0.8 2 | 4.3 ± 0.9 2 | 0.40 (1.04–(−0.15)) 18 | ||||||
| CG | 0.59 (1.43–(−4.51)) 3,18 | 0.1 (−0.3–0.8) 3,18 | NI | NI | 0.49 (1.09–(−0.99)) 18 | ||||||
|
| ST: | ||||||||||
| Sukala et al. [ | 2012 | ET | 0.8 ± 0.4 2,12 | 0.6 ± 0.4 2,12 | −0.2 ± 0.4 2,12 | NI | NI | NI | NI | NI | NI |
| ST | 0.6 ± 0.5 2,12 | 0.5 ± 0.5 2,12 | −0.2 ± 0.5 2,12 | ||||||||
| Jorge et al. [ | 2011 | ET | 14.35 ± 4.51 2,16 | 12.95 ± 3.41 2,16 | NI | 21.15 ± 1.44 2 | 21.06 ± 1.36 2 | NI | 2.38 ± 1.31 2 | 2.46 ± 1.26 2 | NI |
| ST | 16.55 ± 2.55 2,16 | 14.39 ± 1.80 2,16 | 21.39 ± 2.60 2 | 26.11 ± 18.43 2 | 2.91 ± 2.44 2 | 4.76 ± 5.18 2 | |||||
| CT | 15.64 ± 3.86 2,16 | 14.14 ± 2.56 2,16 | 20.93 ± 0.86 2 | 20.23 ± 0.83 2 | 3.47 ± 1.40 2 | 3.10 ± 1.08 2 | |||||
| CG | 15.05 ± 4.22 2,16 | 12.24 ± 4.31 2,16 | 23.69 ± 9.81 2 | 21.29 ± 0.91 2 | 2.29 ± 0.46 2 | 2.74 ± 1.10 2 | |||||
|
| |||||||||||
CG—control group; CRP—C-reactive protein; CT—combined training; ET—endurance training; IL-6—interleukin 6; N/A—not applicable; NI—no information; post—after intervention; pre—before intervention; ST—strength training; TNF-α—tumor necrosis factor; 1 Only statistically significant values are shown; 2 Mean ± standard deviation; 3 Data from figure; 4 6th week of intervention; 5 12th week of intervention; 6 Least square means (means adjusted for baseline) with (95% confidence intervals); 7 Relative changes; 8 Mean and 95% confidence intervals; 9 Converted values; 10 High-intensity interval endurance training; 11 Moderate-intensity continuous endurance training; 12 Data shown as log; 13 Means ± standard error; 14 Means (range); 15 Adjusted values; 16 hsCRP; 17 Bonferroni correction; 18 Median (range); a Studies marked with the same letters were conducted in the same population.
Figure 2Forest plots of the effect of different training programmes on CRP levels: (A) ET vs. ST—random model; (B) ET vs. CT—fixed model; (C) ST vs. CT—random model. CI—confidence interval; CT—combined training; ET—endurance training; ST—strength training; Std diff—standard differences [14,15,16,21,22,23,25,40,48].
Figure 3Forest plots of the effect of different training programmes on IL-6 levels: (A) ET vs. ST—fixed model; (B) ET vs. CT—random model; (C) ST vs. CT—fixed model. CI—confidence interval; CT—combined training; ET—endurance training; ST—strength training; Std diff—standard differences [16,21,23,24,25,40,46,47].
Figure 4Forest plots of the effect of different training programmes on TNF-α levels: (A) ST vs. CT—fixed model; (B) ET vs. ST—random model; (C) ET vs. CT—fixed model. CI—confidence interval; CT—combined training; ET—endurance training; ST—strength training; Std diff—standard differences [16,21,23,25,38,40].
Adipokines levels in studied populations.
| Author | Year | Group | Leptin [µg/mL] | Adiponectin [µg/mL] | Visfatin [ng/mL] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Changes | Pre | Post | Changes | Pre | Post | Changes | |||
| Mohammad Rahimi et al. [ | 2020 | ET | NI | NI | NI | 2660 ± 820 2,3,4 | 6520 ± 990 2,3,4 | 3860 2 (145.1% 5) | NI | NI | NI |
| ST | 2790 ± 940 2,3,4 | 4420 ± 1250 2,3,4 | 1670 2 (59.85% 5) | ||||||||
| CT | 2700 ± 690 2,3,4 | 6440 ± 680 2,3,4 | 3700 2 (137.04% 5) | ||||||||
| CG | 2660 ± 820 2,3,4 | 2700 ± 860 2,3,4 | NI | ||||||||
|
| ET, ST, CT: | ||||||||||
| Christensen et al. [ | 2019 | ET | NI | NI | NI | NI | 17.30 (14.94–19.65) 2,6 | −0.69 (−3.04–1.67) 2,6 | NI | NI | NI |
| −2.5 7 (−17.112.2)% 5,6 | |||||||||||
| ST | 16.79 (14.40–19.21) 2,6 | −1.20 (−3.62–1.23) 2,6 | |||||||||
| −9.5 7 (−24.7–5.7)% 5,6 | |||||||||||
| CT | 17.50 (14.81–20.18) 2,6 | −0.49 (−3.17–2.20) 2,6 | |||||||||
| 1.0 7 (−15.8–17.8)% 5,6 | |||||||||||
| Nunes et al. [ | 2019 | ET | 22.57 (16.13–29.02) 2,8 | 17.59 (11.16–24.02) 2,8 | −4.98 (−9.78–(−0.19)) 2,8 | 4.35 (3.02–5.68) 2,8 | 4.71 (3.59–5.82) 2,8 | 0.35 (−0.96–1.67) 2,8 | NI | NI | NI |
| −28.38 (−55.59–(−1.06))% 2,5,8 | 8.12 (−7.84–13.58)% 2,5,8 | ||||||||||
| CT | 21.33 (15.17–27.49) 2,8 | 17.42 (12.91–21.92) 2,8 | −3.91 (−11.62–3.80) 2,8 | 5.12 (4.02–6.23) 2,8 | 3.00 (1.96–4.05) 2,8 | −2.12 (−3.59–(−0.65))2,8 | |||||
| −18.34 (−54.49–17.8)% 2,5,8 | −41.37 (−70.05–(−12.69))% 2,5,8 | ||||||||||
|
| |||||||||||
| Oh et al. [ | 2017 | ET 9 | NI | NI | −2.18 ± 0.89 4,11 | NI | NI | −0.016 ± 0.01 4,12 | NI | NI | NI |
| ET 10 | −1.45 ± 1.01 4,11 | −0.011 ± 0.018 4,12 | |||||||||
| ST | −1.92 ± 0.68 4,11 | −0.026 ± 0.021 4,12 | |||||||||
|
| ET 9, ST: | ||||||||||
| Soori et al. [ | 2017 | ET | NI | NI | NI | NI | NI | NI | 2.2 ± 0.8 4,11 | 1.6 ± 0.6 4,11 | −0.62 2 |
| ST | 1.7 ± 1 4,11 | 1.8 ± 0.84,11 | NI | ||||||||
| CT | 2.8 ± 0.9 4,11 | 2 ± 0.7 4,11 | −0.86 2 | ||||||||
| CG | 2 ± 0.9 4,11 | 1.7 ± 0.3 4,11 | NI | ||||||||
|
| |||||||||||
| Tayebi et al. [ | 2016 | ET | NI | NI | NI | NI | NI | NI | NI | 9.8 ± 0.4 4,13 | NI |
| ST | 10.7 ± 0.5 4,13 | ||||||||||
| CT | 8.7 ± 0.3 4,13 | ||||||||||
|
| |||||||||||
| Kadoglou et al. [ | 2013 | ET | NI | NI | NI | NI | NI | NI | 35 ± 8 4,11 | 24 ± 9 4,11 | NI |
| ST | 31 ± 8 4,11 | 33 ± 9 4,11 | |||||||||
| CT | 36 ± 8 4,11 | 24 ± 8 4,11 | |||||||||
| CG | 31 ± 8 4,11 | 30 ± 9 4,11 | |||||||||
|
| |||||||||||
| Venojärvi et al. [ | 2013 | ET | 14.1 ± 2.8 14 | NI | −3.8 ± 1.2 14 | 11.2 ± 1.3 14 | NI | 0.0 ± 0.8 14 | NI | NI | NI |
| ST | 11.5 ± 1.4 14 | −0.9 ± 0.9 14 | 10.4 ± 1.1 14 | 0.9 ± 0.6 14 | |||||||
| CG | 7.6 ± 1.3 14 | −0.2 ± 0.9 14 | 12.1 ± 1.5 14 | 0.2 ± 0.7 14 | |||||||
|
| |||||||||||
| Asad et al. [ | 2012 | ET | NI | NI | NI | 16.67 ± 2.35 11 | 17.56 ± 1.51 11 | NI | NI | NI | NI |
| ST | 16.67 ± 2.35 11 | 17.56 ± 1.51 11 | |||||||||
| CT | 17.00 ± 5.37 11 | 20.38 ± 7.61 11 | |||||||||
| CG | 20.30 ± 8.35 11 | 18.80 ± 2.69 11 | |||||||||
| Sukala et al. [ | 2012 | ET | NI | NI | NI | 6.7 ± 3.3 11 | 6.7 ± 3.2 11 | 0.1 ± 2.2 11 | NI | NI | NI |
| ST | 5.6 ± 1.9 11 | 5.6 ± 2.2 11 | 0.0 ± 1.4 11 | ||||||||
| Jorge et al. [ | 2011 | ET | NI | NI | NI | 5.58 ± 5.73 11 | 3.38 ± 2.22 11 | NI | 112.24 ± 45.83 11 | 131.54 ± 58.38 11 | NI |
| ST | 4.45 ± 4.12 11 | 5.13 ± 4.30 11 | 112.11 ± 42.85 11 | 142.25 ± 51.04 11 | |||||||
| CT | 5.98 ± 3.43 11 | 6.58 ± 5.44 11 | 116.19 ± 75.41 11 | 127.46 ± 45.22 11 | |||||||
| CG | 5.07 ± 5.50 11 | 3.75 ± 2.93 11 | 103.57 ± 55.06 11 | 134.12 ± 72.06 11 | |||||||
|
| ET, ST, CT, CG: | ||||||||||
| Ahmadizad et al. [ | 2007 | ET | NI | NI | NI | 9.5 ± 3.4 4,11 | 9.45 ± 1.1 4,11 | NI | NI | NI | NI |
| ST | 11.3 ± 1.4 4,11 | 9.7 ± 2.5 4,11 | |||||||||
| CG | 10.3 ± 1.9 4,11 | 12.1 ± 4.4 4,11 | |||||||||
| Hara et al. [ | 2005 | ET | 7.3 ± 2.8 11 | 6.0 ± 2.6 11 | NI | 3.7 ± 2.2 11 | 4.0 ± 1.9 11 | NI | NI | NI | NI |
| CT | 5.9 ± 2.0 11 | 5.4 ± 2.3 11 | 6.2 ± 2.0 11 | 6.6 ± 2.5 11 | |||||||
| CG | 8.8 ± 2.3 11 | 8.6 ± 2.5 11 | 4.0 ± 1.2 11 | 4.2 ± 1.3 11 | |||||||
|
| ET: | CT vs. CG, ET: | |||||||||
CG—control group; CT—combined training; ET—endurance training; N/A—not applicable; NI—no information; post—after intervention; pre—before intervention; ST—strength training. 1 Only statistically significant values are shown; 2 Converted values; 3 High molecular weight-adiponectin; 4 Data from figure; 5 Relative changes; 6 Least square means (means adjusted for baseline) with (95% confidence intervals); 7 Value after Bonferroni; 8 correction Mean and 95% confidence intervals; 9 High-intensity interval endurance training; 10 Moderate-intensity continuous endurance training; 11 Mean ± standard deviation; 12 Data shown as log; 13 Adjusted mean ± standard error; 14 Mean ± standard error;15 ANOVA split-plot in time design.
Figure 5Forest plots of the effect of different training programmes on leptin levels: (A) ET vs. ST—fixed model; (B) ET vs. CT—fixed model. CI—confidence interval; CT—combined training; ET—endurance training; ST—strength training; Std diff—standard differences [19,40,45,47].
Figure 6Forest plots of the effect of different training programmes on adiponectin levels: (A) ET vs. ST—random model; (B) ET vs. CT—random model; (C) ST vs. CT—random model. CI—confidence interval; CT—combined training; ET—endurance training; ST—strength training; Std diff—standard differences [19,20,21,22,25,40,41,42,45,47].
Figure 7Forest plots of the effect of different training programmes on visfatin levels: (A) ET vs. ST—random model; (B) ET vs. CT—fixed model; (C) ST vs. CT—random model. CI—confidence interval; CT—combined training; ET—endurance training; ST—strength training; Std diff—standard differences [15,18,25,37].
Figure 8Traffic−light plot of the risk of bias [14,15,16,17,18,19,20,21,22,23,24,25,37,38,39,40,41,42,43,44,45,46,47,48].
Figure 9Summary plot of the risk of bias.